Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Post by professional11on Jun 09, 2012 10:45pm
514 Views
Post# 19996874

Lux data was expected May 2012

Lux data was expected May 2012

https://www.clinicaltrials.gov/ct2/show/NCT01243983?term=LX211&rank=4

Primary outcome data was originally expected to be released by Lux May 2012. Given the delays in recruitment (Lux is still recruiting patients according to their website -- https://uveitisresearch.com/index.html), I expect that the "primary outcome" data for the phase 3 study will be released later this year, with secondary outcome data in Q1 2013.

P11

<< Previous
Bullboard Posts
Next >>